Coronavirus (COVID-19)
Learn more
May 09, 2017
Sponsor: Hoffmann-La Roche
Number: GO29537
Eligible patients who enroll in the study will be randomly assigned (by chance) to this Phase III, multicenter, open-label study which is designed to evaluate the safety and efficacy of Atezolizumab (MPDL3280A) in combination with Carboplatin + Nab-Paclitaxel compared with treatment with Carboplatin + Nab-Paclitaxel in chemotherapy-naive patients with Stage IV non-squamous non-small cell lung cancer (NSCLC). Phase III trials: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely. Stage IV is non-small cell lung cancer which has spread from the site of the primary (original) tumor only to surrounding tissue.
Who’s eligible:
Available at: Backus Hospital- Eastern Connecticut Hematology and Oncology.
Referral Line: 860.972.4700
Get the latest healthcare news directly in your inbox.
Sign up for text alerts / Text MoreLife to 31996.